Mayor Wu Appoints New Members, Chair of BPL Board of Trustees

Jonathan Lavine and Julie Kim appointed, Dr. Liu succeeds as chair

BOSTON, MA – June 5, 2024 The Boston Public Library (BPL) announced today that Jonathan Lavine and Julie Kim have been appointed by Mayor Michelle Wu to serve on the Boston Public Library Board of Trustees.   Lavine and Kim will replace outgoing trustees Representative Chynah Tyler and Priscilla Douglas.   

“Jonathan Lavine and Julie Kim bring important expertise and passion for the community to the Boston Public Library, and it is a pleasure to welcome them into stewardship of one of our city’s most historic and fundamental institutions,” said Mayor Michelle Wu. “I’m grateful to Chair Douglas and Representative Tyler for their service and leadership of this board, and I look forward to continuing to celebrate the impact of the BPL on all the residents of Boston’s neighborhoods.” 

Mayor Wu also announced the appointment of Dr. Raymond Liu to succeed Priscilla Douglas as Chair of the Board of Trustees.

“I am grateful to Mayor Wu for the opportunity to serve as Chair of this historic board,” said Dr. Liu“The BPL is in a period of unprecedented growth and innovation, and I am confident that the future holds even greater thingsI look forward to working closely with President David Leonard and the entire staff of the BPL, along with incoming trustees Jonathan Lavine and Julie Kim, to continue the work so capably stewarded by outgoing Chair Douglas and Representative Tyler.”

Douglas held the position of Board Chair for a five-year termHer tenure as Chair spanned the COVID-19 epidemic, during which time the BPL could continue its operations despite its doors being closed, deploying programs such as BPL to Go, which included book bundles, craft kits, and home digital connectivity kits.   In addition to drafting the new equity and land acknowledgment statement now read at each trustee meeting, Douglas also presided over the ribbon cuttings of significant branch renovations and reconstructions, including projects at Roslindale, Roxbury, and Adams Street.  Douglas will continue to serve the City of Boston as a member of the Boston Cultural Council, opens a new window

In addition to the appointment of Dr. Liu, Lavine, and Kim, Mayor Wu reappointed Jeffrey Hawkins, opens a new window as a trusteeHawkins sits on the BPL Board of Trustees as the representative of the Boston Public Library Fund, opens a new window. 

Incorporated in 1878, the Boston Public Library Board of Trustees establishes policies and sets the strategic goals of the library, oversees the general operating and administrative policies, and acts as an agent of public trust governing the library. The BPL Board of Trustees works together with the library president to carry out responsibilities that involve governance and policy making, financial and development oversight, and the work of strategic planning.  

The Board of Trustees consists of 15 trustees, all residents of the Commonwealth of Massachusetts, and appointed by the Mayor of Boston. Trustees hold their office for a term of five years and until their successor is appointed.  The BPL Board of Trustees works together with the library president to carry out responsibilities that involve governance and policymaking, financial and development oversight, and setting strategy.  



Dr. Raymond Liu is the Vice President of Mass General Brigham Global Advisory, serving as the leader of the system-wide international advisory services team, with direct responsibility for strategy, operations, and financial performance of Global Advisory. Global Advisory collaborates with governments, international institutions, healthcare systems, and investors to drive transformative, sustainable change that delivers best-in-class local and community healthcare. Global Advisory leads enterprise-wide international advisory efforts, focusing on strategy, system coordination, business development, and project delivery on behalf of Mass General Brigham healthcare system and its member hospitals.   

Dr. Liu brings over a decade of experience and leadership in clinical and hospital operations through his previous roles at Massachusetts General Hospital. Dr. Liu previously served as the Associate Chair for Business Strategy and Analytics for the Department of Radiology, the Director of the Radiology Consulting Group, and the Service Chief for Operational Redesign. His portfolio includes extensive work in operational efficiency, data analytics, and new business development, building upon his experience as a healthcare consultant for McKinsey & Co. Nationally, Dr. Liu serves on the Board of Directors for the Society of Interventional Radiology, where he is a Fellow, Treasurer, and former Chair of the Health Policy & Economics Division.   

Dr. Liu graduated from Harvard College and Harvard Medical School and went on to complete dual residencies in pediatrics and diagnostic radiology at New York Presbyterian Hospital/Columbia University. Dr. Liu returned to Boston to complete his fellowship in interventional radiology at Brigham and Women's Hospital, including training at Children's Hospital of Boston.  

Dr. Liu focuses his clinical interests in the fields of interventional oncology and pediatric interventions with a special interest in Hereditary Hemorrhagic Telangiectasia and the treatment of pulmonary arteriovenous malformations. His research interests are focused on the economics of interventional radiology, operational efficiency, and cost-effectiveness. Dr. Liu lives in Brookline, MA with his wife and three children.  


Julie Kim is the President of the U.S. Business Unit, the U.S. Country Head, and a member of Takeda’s Executive Team. The U.S. Business Unit portfolio encompasses gastroenterology, neuroscience, plasma-derived therapies, and rare diseases. 

She joined Takeda in 2019 through the acquisition of Shire, where she held several diverse roles with increasing responsibility. As part of Takeda, she became the President of the Plasma-Derived Therapies Business Unit, a position she occupied until April of 2022 when she became President of the U.S. Business Unit and U.S. Country Head. 

Julie has 30 years of experience in health care, with leadership positions at global, regional, country, and functional levels. In the biopharmaceutical industry, her experiences have spanned a variety of therapeutic areas, international market access, country and regional general management, marketing, and emerging market development.  

Julie is known for strong, collaborative, and inclusive leadership that enables Takeda to meet the needs of the people the company serves while driving innovations that will improve patients’ lives. Her global outlook, a result of having worked in many countries in Europe, Asia, and Latin America, as well as having lived in the U.K., Switzerland, and the U.S., has helped her create teams that are diverse in multiple dimensions to enable inclusive decision-making that keeps the patient at the center.   

Julie serves on the boards of directors for PhRMA, an organization that represents the country’s leading innovative biopharmaceutical research companies, and Croda International, a company that leverages smart science to create high-performance ingredients and technologies that improve lives.She was named one of Boston Magazine’s 150 Most Influential Bostonians in 2024, Boston’s 50 Most Influential Asian American Pacific Islanders in 2023, The 2022 PharmaVoice 100 list, and  Fierce Pharma’s list of 2020’s Fiercest Women in Life Sciences.  

She earned an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in economics from Dartmouth College. She resides with her family in the Boston area. 


Jonathan Lavine is Chair of Bain Capital and served as Co-Managing Partner of the firm from 2016 – 2024.  Mr. Lavine founded Bain Capital Credit, formerly known as Sankaty Advisors, in 1998, and also created Bain Capital’s Special Situations investment strategy group.  Mr. Lavine joined Bain Capital’s private equity group in 1993.  Prior to joining Bain Capital, he was a consultant at McKinsey & Company.  He began his career at Drexel Burnham Lambert in mergers and acquisitions. 

Mr. Lavine and his wife, Jeannie, formed and now oversee the Crimson Lion Foundation, which delivers financial resources to a wide variety of nonprofit organizations focused on leveling the playing field for individuals and families.  The foundation works to address pressing social challenges in the areas of education, community and public service, health and welfare, discrimination, and poverty by supporting organizations that serve to strengthen society through research, innovation, public policy, direct service, and advocacy.   

They are longtime supporters of Columbia University, where Mr. Lavine is Chair Emeritus of the Trustees of the University; and Harvard University, where they endowed the Lavine Family Humanitarian Studies Initiative at the Harvard School of Public Health and provided substantial support to fund scholarships for first-generation students at Harvard Business School.   

Mr. Lavine is the 2017 recipient of Columbia University’s Alexander Hamilton Medal, the highest honor awarded to a member of the college community for distinguished service.  He is a past recipient of Columbia’s John Jay Award for professional achievement, Columbia’s David Truman Award for outstanding contribution to academic affairs, the Dean’s Leadership Award for the Class of 1988 25th Reunion, Columbia/Barnard Hillel’s Seixas Award, Opportunity Nation’s American Dream Award, Voices for National Service Citizen Service Award and of the New England Anti-Defamation League’s Distinguished Community Service Award.  He is the first recipient of the London School of Economics Alternative Investments Conference’s “Distinguished Speaker Honour.”  Mr. Lavine was appointed a Member of the United States Holocaust Memorial Museum Council by President Obama and reappointed by President Biden.  He is also a member of the investor group and a director of the Boston Celtics. 

Mr. Lavine graduated from Columbia College, Phi Beta Kappa, and Magna Cum Laude, and holds an M.B.A. with Distinction from Harvard Business School.  He received an Honorary Doctor of Laws degree from Columbia University in 2023.